US2012009251A1PendingUtilityA1

Cholestanol derivative for combined use

41
Assignee: YAZAWA SHINPriority: Mar 5, 2008Filed: Sep 19, 2011Published: Jan 12, 2012
Est. expiryMar 5, 2028(~1.6 yrs left)· nominal 20-yr term from priority
Inventors:Shin YazawaToyo NishimuraTakayuki Asao
A61P 35/00A61P 43/00A61K 31/337A61K 31/724A61K 31/664A61K 31/4745A61K 31/282A61K 31/513A61K 9/127C07J 17/005A61K 31/7072A61K 31/704A61K 45/06A61K 33/243
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a cancer chemotherapeutic agent which has fewer side effects and excellent efficacy. The cancer chemotherapeutic agent of the invention includes a cholestanol derivative represented by formula (1): (wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, Gal-, or GlcNAc-) or a cyclodextrin inclusion compound thereof, and an anti-cancer agent.

Claims

exact text as granted — not AI-modified
1 . A cancer chemotherapeutic agent comprising, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- or a cyclodextrin inclusion compound thereof, and an anti-cancer agent. 
     
     
         2 . The cancer chemotherapeutic agent according to  claim 1 , wherein, in formula (1), G is GlcNAc-Gal-. 
     
     
         3 . The cancer chemotherapeutic agent according to  claim 1 , wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil. 
     
     
         4 . The cancer chemotherapeutic agent according to  claim 3 , wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cisplatin, Oxaliplatin, Cyclophosphamide, and Irinotecan. 
     
     
         5 . The cancer chemotherapeutic agent according to  claim 1 , which is a compounding agent. 
     
     
         6 . The cancer chemotherapeutic agent according to  claim 1 , which is in the form of a kit including a drug containing a cholestanol derivative and a drug containing an anti-cancer agent. 
     
     
         7 . The cancer chemotherapeutic agent according to  claim 6 , wherein the drug containing a cholestanol derivative is a liposomal formulation. 
     
     
         8 . A method of producing a chemotherapeutic agent for the treatment of cancer, by combining a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- or a cyclodextrin inclusion compound thereof and an anti-cancer agent. 
     
     
         9 . A method for cancer chemotherapy, comprising administering, in combination, a cholestanol derivative represented by formula (1): 
       
         
           
           
               
               
           
         
       
       wherein G represents GlcNAc-Gal-, GlcNAc-Gal-Glc-, Fuc-Gal-, Gal-Glc-, or Gal- or a cyclodextrin inclusion compound thereof and an anti-cancer agent, to a patient in need thereof. 
     
     
         10 . The method for cancer chemotherapy according to  claim 9 , wherein the cholestanol derivative or a cyclodextrin inclusion compound thereof and the anti-cancer agent are administered to a patient in need thereof simultaneously, or separately and intermittently. 
     
     
         11 . The method for cancer chemotherapy according to  claim 9 , wherein, in formula (1), G is GlcNAc-Gal-. 
     
     
         12 . The method for cancer chemotherapy according to  claim 9 , wherein the anti-cancer agent is one or more species selected from the group consisting of a taxane anti-cancer agent, a platinum complex anti-cancer agent, a pemetrexed compound, and fluorouracil. 
     
     
         13 . The method for cancer chemotherapy according to  claim 12 , wherein the anti-cancer agent is one or more species selected from the group consisting of Paclitaxel, Docetaxcel, Pemetrexed, 5-FU, Cisplatin, Oxaliplatin, Cyclophosphamide, and Irinotecan. 
     
     
         14 . The method for cancer chemotherapy according to  claim 9 , wherein the drug containing a cholestanol derivative is a liposomal formulation. 
     
     
         15 . The method for cancer chemotherapy according to  claim 9 , wherein the anticancer agent is Cisplatin. 
     
     
         16 . The cancer chemotherapeutic agent according to  claim 1 , wherein the anticancer agent is Cisplatin.

Join the waitlist — get patent alerts

Track US2012009251A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.